Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparative multicenter trial
Braz. j. infect. dis
;
12(3): 202-209, June 2008. tab
Article
Dans Anglais
| LILACS
| ID: lil-493648
ABSTRACT
Community-Acquired Pneumonia (CAP) is a major public health problem. In Brazil it has been estimated that 2,000,000 people are affected by CAP every year. Of those, 780,000 are admitted to hospital, and 30,000 have death as the outcome. This is an open-label, non-comparative study with the purpose of evaluating efficacy, safety, and tolerability levels of IV azithromycin (IVA) and IV ceftriaxone (IVC), followed by oral azithromycin (OA) for the treatment of inpatients with mild to severe CAP. Eighty-six patients (mean age 56.6 ± 19.8) were administered IVA (500mg/day) and IVC (1g/day) for 2 to 5 days, followed by AO (500mg/day) to complete a total of 10 days. At the end of treatment (EOT) and after 30 days (End of Study - EOS) the medication was evaluated clinically, microbiologically and for tolerability levels. Out of the total 86-patient population, 62 (72.1 percent) completed the study. At the end of treatment, 95.2 percent (CI95 88.9 percent - 100 percent) reported cure or clinical improvement; at the end of the study, that figure was 88.9 percent (CI95 74.1 percent - 91.7 percent). Out of the 86 patients enrolled in the study, 15 were microbiologically evaluable for bacteriological response. Of those, 6 reported pathogen eradication at the end of therapy (40 percent), and 8 reported presumed eradication (53.3 percent). At end of study evaluation, 9 patients showed pathogen eradication (50 percent), and 7 showed presumed eradication (38.89 percent). Therefore, negative cultures were obtained from 93.3 percent of the patients at EOT, and from 88.9 percent at the end of the study. One patient (6.67 percent of patient population) reported presumed microbiological resistance. At study end, 2 patients (11.11 percent) still reported undetermined culture. Uncontrollable vomiting and worsening pneumonia condition were reported by 2.3 percent of patients. Discussion and Conclusion Treatment based on the administration of IV azithromycin...
Texte intégral:
Disponible
Indice:
LILAS (Amériques)
Sujet Principal:
Ceftriaxone
/
Azithromycine
/
Pneumopathie bactérienne
/
Antibactériens
Type d'étude:
Essai clinique contrôlé
/
Étude observationnelle
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Adolescent
/
Adulte
/
Adulte très âgé
/
Aged80
/
Humains
langue:
Anglais
Texte intégral:
Braz. j. infect. dis
Thème du journal:
Maladies transmissibles
Année:
2008
Type:
Article
Pays d'affiliation:
Brésil
Institution/Pays d'affiliation:
Catholic University of Campinas/BR
/
FUNFARME/BR
/
Federal University of Juiz de Fora/BR
/
Federal University of Paraná/BR
/
Federal University of São Paulo/BR
/
General Hospital Roberto Santos/BR
/
General Hospital of Itapecerica da Serra - OSS Seconci/BR
/
Irmandade da Santa Casa de Misericórdia of Porto Alegre/BR
/
Irmandade da Santa Casa de Misericórdia of São Paulo/BR
/
Nossa Senhora da Conceição Hospital/BR
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS